Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.

© John Cairns

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website.

The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) yesterday produced guidelines for the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca.

The WHO has recommended that two standard doses of ChAdOx1 nCoV-19 be administered at an 8- to 12-week interval in people aged 18 years and older. This dosing regimen was shown in clinical trials to be safe and effective in preventing symptomatic COVID-19, with no severe cases and no hospitalisations from COVID-19 more than 14 days after the second dose.

The new guidance marks a key step towards the University and AstraZeneca’s goal of providing global access to the vaccine, which is being made available on a not-for-profit basis during the pandemic. The vaccine is easily manufactured, transported and stored at domestic fridge temperature (2-8 degrees C), so can be easily administered in existing healthcare settings, allowing for the vaccine to be deployed rapidly around the world.

Andrew Pollard, Professor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford vaccine trial, said: ‘The new guidance from WHO is an important milestone in extending access to the Oxford-AZ vaccine to all corners of the world and providing further endorsement that after rigorous scrutiny by the WHO Strategic Advisory Group of Experts the vaccine can be used to help protect populations from the coronavirus pandemic.’

Sarah Gilbert, Professor of Vaccinology, and Chief Investigator on the Oxford vaccine trial, said: ‘It is excellent news that the WHO has recommended use of the SARS CoV-2 vaccine first produced in Oxford. This decision paves the way to more widespread use of the vaccine to protect people against COVID-19 and gain control of the pandemic.’

Similar stories

Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots

COVID-19

Andrew Pollard writes about vaccine equity in his article for The Conversation.

Increasing vaccine uptake among ethnic minorities

COVID-19 Public Engagement

Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.

COVID-19 elimination, not mitigation, best for health, economy and civil liberties – Oxford study

COVID-19

Countries which aimed to eliminate COVID-19 registered fewer deaths, better economic performance, and fewer restrictions and lockdowns, according to an article in The Lancet.

Alternating vaccines trial expands to include two additional vaccines

COVID-19

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

COVID-19

Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Oxford University researchers release cheap, quick COVID-19 antibody test

COVID-19

The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.